Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Fried S, Shouval R, Varda-Bloom N, Besser MJ, et al. Leuk Lymphoma 2022;63:3385-3393.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fried S, Shouval R, Varda-Bloom N, Besser MJ, et al. Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Leuk Lymphoma 2022;63:3385-3393.
PMID: 36111694